E2 ModeratePreliminaryPEM ?Case-ControlPeer-reviewedMachine draft
A comparison of genome-wide association analyses of persistent symptoms after Lyme disease, fibromyalgia, and myalgic encephalomyelitis - chronic fatigue syndrome.
Hirsch, Annemarie G, Justice, Anne E, Poissant, Amy et al. · BMC infectious diseases · 2025 · DOI
Quick Summary
Researchers studied the genes of people who had Lyme disease to understand why some develop lasting symptoms even after treatment. They found two genetic regions that might be involved in persistent Lyme disease symptoms, with one linked to a protein called MARC2 that affects immune function. When they checked whether these same genetic changes appeared in people with fibromyalgia or ME/CFS, they did not find the same patterns, suggesting these conditions may have different genetic roots.
Why It Matters
Although this study focuses on Lyme disease, it addresses the hypothesis that ME/CFS, fibromyalgia, and post-Lyme disease syndrome share overlapping biological mechanisms. The findings that these conditions do not share the identified genetic variants suggest ME/CFS has distinct genetic underpinnings, which could guide future research into ME/CFS-specific genetic risk factors and immune dysfunction.
Observed Findings
- Two genetic loci reached suggestive significance in PTLDS: rs77857587 (near IRX1) and rs10833979 (near GAS2)
- The lead PTLDS variant rs77857587 is in high linkage disequilibrium with a protein quantitative locus (rs111774530) affecting MARC2 protein levels
- 19.4% of treated Lyme disease patients (695 of 3,585) met criteria for persistent post-treatment symptoms
- Neither PTLDS locus was significantly associated with fibromyalgia (5,041 cases) or ME/CFS (2,268 cases) in the same biorepository
Inferred Conclusions
- Immune checkpoint dysregulation, potentially mediated through MARC2, may contribute to PTLDS pathophysiology
- PTLDS has distinct genetic underpinnings compared to fibromyalgia and ME/CFS, suggesting these conditions are not driven by identical genetic risk factors
- Larger replication studies are needed to validate these suggestive findings and determine their clinical significance
Remaining Questions
- Do the identified genetic variants replicate in independent PTLDS cohorts, and what are their effect sizes?
- What are the functional consequences of MARC2 variations on immune checkpoint regulation and symptom severity in PTLDS?
- What distinct genetic factors (if any) contribute to ME/CFS compared to PTLDS and fibromyalgia?
What This Study Does Not Prove
This study does not prove that MARC2 or the identified variants cause PTLDS; it only identifies genetic associations that require validation in larger populations. The lack of overlap between PTLDS, fibromyalgia, and ME/CFS loci does not rule out shared non-genetic pathways (e.g., environmental triggers, infections, inflammatory cascades). Suggestive-threshold findings (P<5×10⁻⁷) fall below genome-wide significance and require replication before clinical application.
Tags
Symptom:Fatigue
Biomarker:Gene Expression
Phenotype:Infection-Triggered
Method Flag:PEM Not DefinedWeak Case DefinitionExploratory Only